

Threshold Pharmaceuticals

STS interim analysis preview

During September the planned interim analysis of the ongoing Phase III soft tissue sarcoma (STS) trial is expected to occur. An independent committee (IDMC) will review efficacy and safety to determine next steps. Of the three possible outcomes, Threshold believes the most likely is that the trial continues as planned with overall survival data then in H215e.

STS is one of the most advanced TH-302 indications

The Phase III STS trial is investigating TH-302 with doxorubicin versus doxorubicin alone in 640 patients; recruitment was completed in December 2013. The primary endpoint is overall survival (OS), and the trial is designed around an expected TH-302 survival benefit of four months (33% increase) and an expected 12-month OS on control arm. The trial design has been agreed with FDA under a Special Protocol Assessment (SPA), meaning the design of the trial is acceptable for approval.

Interim analysis has three potential outcomes

An interim analysis when 235 events (deaths) have occurred is expected in September, when the IDMC will review both efficacy and safety data. There are three possible outcomes: (1) the trial continues as planned, with OS data then expected in H215; (2) the trial is stopped early for benefit if superiority of TH-302 is clearly established; this would need TH-302 to demonstrate around a 45% OS improvement ($p=0.0023$); and (3) the trial is stopped early, either for unacceptable safety, or if TH-302 is unlikely to show a benefit if the trial continues.

Most likely outcome is trial continuation

We believe it is unlikely that the trial will be stopped for a lack of benefit based on a 21.5-month median OS in a previous Phase II open-label trial. Safety has also been under regular IDMC review during the Phase III trial. While it is possible that TH-302 could demonstrate an efficacy benefit sufficient to stop the trial early, this would require a clear demonstration of efficacy with a 45% OS improvement, substantially higher than planned for in the trial design. Threshold believes, and we agree, that the most common outcome is continuation of the trial as planned.

Valuation: EV of around \$210m

End-June net cash of \$75.2m implies an EV of only c \$210m. TH-302 has potential across a broad range of tumours and Phase III trials in both STS and pancreatic cancer are ongoing, in addition to a \$525m deal with Merck KGaA.

Consensus estimates

Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/12	5.9	(71.1)	(1.31)	0.0	N/A	N/A
12/13	12.5	(28.2)	(0.49)	0.0	N/A	N/A
12/14e	15.5	(22.8)	(0.45)	0.0	N/A	N/A
12/15e	18.8	(32.1)	(0.52)	0.0	N/A	N/A

Source: Bloomberg

Pharma & biotech

10 September 2014

Price \$4.80
Market cap \$285m

Share price graph



Share details

Code THLD
Listing NASDAQ
Shares in issue 59.3m

Business description

Threshold Pharmaceuticals is a US oncology company focused on tumour hypoxia, a low-oxygen condition found in most solid tumours and some blood cancers. TH-302 is in Phase III for STS and pancreatic cancer, in addition to trials in multiple other cancers and is partnered with Merck KGaA.

Bull

- TH-302 has potential in a number of cancer indications, as both monotherapy in some cancers, and in combination with chemotherapy and antiangiogenics.
- Merck KGaA funds 70% of TH-302 development.
- Solid cash position of \$75.2m (end June).

Bear

- TH-302 could fail to show survival benefit in STS.
- Oncology is a highly competitive space.
- Single-product risk.

Analysts

Dr Philippa Gardner +44 (0)20 3681 2521
Emma Ulker +44 (0)20 3077 5738

healthcare@edisongroup.com

QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2014 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Threshold Pharmaceuticals and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2014]. "FTSE(r)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.